Registry‐Based Frequency of Molecularly Confirmed Osteogenesis Imperfecta in a Swiss Cohort of Individuals With Connective Tissue Disorders
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.64016 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Olivia Abegglen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Connective Tissue Unit, Division of Metabolism and Children's Research Center, University Children's Hospital Zurich and University of Zurich, Zurich…. Hauptthemen laut MEDLINE: Osteogenesis Imperfecta, Connective Tissue Diseases, Collagen Type I. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Bangerter-Rhyner Foundation and the Uniscientia Foundation, Olga Mayenfisch Foundation, Swiss National Science Foundation.
Abstract (Originalsprache)
Patient registries play a crucial role in advancing our understanding of rare diseases, enabling the collection of comprehensive clinical and molecular data that inform diagnosis, treatment, and management strategies and advance our understanding of rare diseases. We showcase the first Swiss registry of 796 patients with suspected or confirmed connective tissue disorders (CTD) who were referred to our center over a period of 26 years between 1995 and 2022. The registry contains information on the natural history, anthropometrics, biochemical, histological, and genetic analyses. 61.3% of patients were referred by other hospitals or genetic specialists, with the primary reasons for referral being suspicion of Ehlers–Danlos syndrome (EDS) (53.6%) and osteogenesis imperfecta (OI) (28.1%). Molecular confirmation of these diagnoses was obtained in 60 cases of EDS and 98 cases of OI through genetic testing. In‐depth analyses of 173 OI patients revealed that the majority of OI cases were caused by mutations in COL1A1 or COL1A2 . Rarer variants were identified in genes involved in collagen synthesis and bone regulation. Genotype–phenotype correlations were observed in a small subset of patients, with a high prevalence of glycine substitutions in COL1A1 and COL1A2 variants associated with severe phenotypes. This registry offers insights into the molecular underpinnings of EDS and OI and underscores the importance of genetic testing for accurate diagnosis and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Connective Tissue Unit, Division of Metabolism and Children's Research Center, University Children's Hospital Zurich and University of Zurich, Zurich, Switzerland.
ORCID-Profile: Marianne Rohrbach
Förderung
- Bangerter-Rhyner Foundation and the Uniscientia Foundation
- Olga Mayenfisch Foundation
- Swiss National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Olga Mayenfisch Stiftung
Zitieren
APA
Abegglen, O., Srikantharupan, S., Zotter, K., Marcionelli, G., Ndarugendamwo, T., Lim, P. J., Giunta, C., Kaufman, C., & Rohrbach, M. (2025). Registry‐Based Frequency of Molecularly Confirmed Osteogenesis Imperfecta in a Swiss Cohort of Individuals With Connective Tissue Disorders. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.64016
Vancouver
Abegglen O, Srikantharupan S, Zotter K, Marcionelli G, Ndarugendamwo T, Lim PJ, et al. Registry‐Based Frequency of Molecularly Confirmed Osteogenesis Imperfecta in a Swiss Cohort of Individuals With Connective Tissue Disorders. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.64016
BibTeX
@article{Abegglen2025,
author = {Abegglen, Olivia and Srikantharupan, Shajanth and Zotter, Kathrin and Marcionelli, Giulio and Ndarugendamwo, Timothée and Lim, Pei Jin and Giunta, Cecilia and Kaufman, Christina and Rohrbach, Marianne},
title = {Registry‐Based Frequency of Molecularly Confirmed Osteogenesis Imperfecta in a Swiss Cohort of Individuals With Connective Tissue Disorders},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.64016}
}
EUVIMED